The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
News|Articles|July 26, 2022
COVID-19 Update: US Vaccinations, Booster Doses, & Global Data as of July 26, 2022
Author(s)Grace Halsey
Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.
Advertisement
US COVID-19 vaccination & booster dose status
US COVID-19 vaccination status according to the Centers for Disease Control and Prevention (CDC) as of July 20, 2022, at 6:00 AM, EDT:
Fully vaccinated plus 2 booster doses:
• Aged ≥50 years 29.7%
• Aged ≥65 years 36.5%
Fully vaccinated plus 1 booster dose:
• Total US population 48.2%
Fully vaccinated in key age groups:
• Total US population 67.2%
• Aged ≥5 years 71.4%
• Aged ≥65 years 91.8%
US confirmed cases of COVID-19 and deaths
Confirmed US cases of COVID-19 and related deaths according to the Johns Hopkins COVID-19 interactive map , as of July 26, 2022 at 5:20 PM, EDT.
3 states with highest number of new cases in past 28 days
• California 513 223
• Texas 328 624
• Florida 296 057
• Total US confirmed cases 90 706 322
• Total US confirmed deaths 1 027 791
Global total COVID-19 confirmed cases, deaths, vaccination doses administered:
• Cases 571 997 454
• Deaths 6 387 881
• Vaccine doses administered 11 933 148 676
Advertisement
Related to this article
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
Advertisement
Advertisement